Silence Therapeutics plc, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, and Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma", 3692.HK), one of the leading biopharmaceutical companies in China, today announced a collaboration to develop siRNAs for three undisclosed targets leveraging Silence's proprietary mRNAi GOLD platform.

Read more...

BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of a new plasma center in Worcester, MA, to help meet the urgent and growing demand for therapies developed from plasma. Plasma donations received at BioLife centers are used by Takeda to make established therapies that treat a range of rare and chronic complex diseases, such as immunodeficiency disorders, for which there are often no alternative treatments. “We’re e

Read more...

Agilent Technologies Inc. announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered. This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly and Comp

Read more...

Deepcell, a life science company pioneering AI-powered cell classification and isolation for basic and translational research, today announced a collaboration with the Levesque Lab at the University of Zurich. The goals of the collaboration are to use Deepcell’s technology to identify and sort rare melanoma cells, profile melanoma tissues to gain a deeper understanding about tumor microenvironment, and enable molecular analyses of the sorted cells. This collaboration brings to

Read more...

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ADC Development Panel, a specialized gene expression tool for use in the rapidly expanding field of Antibody Drug Conjugates (ADCs). Created in collaboration with leading pharmaceutical and clinical scientists, this novel panel is designed to provide molecular insights into important biological questions and challenges of oncology th

Read more...

MSP Recovery, LLC, a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader today announced the formation of a partnership to transform legal, data, and healthcare delivery into one united ecosystem. MSP will provide the detailed underlying legal, data and healthcare knowledge, utilizing Palantir Foundry as the foundation of the data ecosystem. “The U.S. healthcare system has the most knowledgeable and qualified doctors and healthcare practitioners,&

Read more...

Parse Biosciences today announced a partnership with Decode Science to provide Parse’s single-cell RNA-seq solution to the Australian and New Zealand markets. Under an agreement between the parties, Decode Science has been appointed a distributor of the Parse product portfolio for Australia and New Zealand. Decode Science will provide customer service, technical support, sales and marketing, distribution, and related logistical efforts for the Parse Whole Transcriptome Kit (WT

Read more...

The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase. The collaboration brings together the translat

Read more...